Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Recent News

bioTheranostics Announces Contract with Three Rivers Provider Network

bioTheranostics Signs Agreement with National PPO Network Prime Health Services

bioTheranostics’ Breast Cancer IndexSM Molecular Test Identifies Risk for Early and Late Breast Cancer Recurrence, Lancet Oncology Study Finds

Recent Publications

Medical Laboratory Observer:
Under Richard Ding’s direction, bioTheranostics focuses on biomarkers to aid in cancer treatment

Journal of Clinical Oncology:
Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute

ASCO Post:
Gene Profiling–guided Therapy May Improve Survival in Patients with Carcinoma of Unknown Primary


bioTheranostics develops and provides innovative oncology tests to support targeted disease management.

bioT3 is a suite of genomic-based tests that provide diagnostic and therapeutic information for metastatic cancer patients at any stage across the continuum of care.

  • CancerTYPE ID® – Molecular classification for definitive diagnosis of tumor type and subtype
    Learn More >
  • CancerTARGET ID – (Formerly PRÉCIS®) Actionable tumor-specific biomarkers for the selection of on-label targeted therapies
    Learn More >
  • CancerTREATMENT ID – Next Generation Sequencing (NGS) + multi-platform biomarkers for comprehensive treatment options
    Learn More >

Breast Cancer IndexSM (BCI) provides full risk assessment, with the unique ability to predict both early and late recurrence, as well as benefit from extended endocrine therapy.
Learn More >

Healthcare Professionals

Learn more about bioT3
Access Clinical Publications
Register for Clinical Updates
Request a Specimen Shipping Kit
Contact Medical Affairs

Patients and Caregivers

Learn More About Metastatic Cancers